Literature DB >> 7787437

Expression of growth factors and growth factor receptors in normal and tumorous human thyroid tissues.

B F van der Laan1, J L Freeman, S L Asa.   

Abstract

A number of growth factors have been implicated as stimuli of thyroid cell proliferation; overexpression of these growth factors and/or their receptors may play a role in the growth of thyroid tumors. To determine if immunohistochemical detection of growth factors and/or their receptors correlates with morphological alterations in proliferative lesions of thyroid, we examined the localization of epidermal growth factor (EGF), transforming growth factor-alpha (TGF-alpha) and their common receptor, EGF-receptor (EGF-R), insulin-like growth factor-1 (IGF-1), IGF-1-receptor (IGF-R) and IGF binding proteins (IGFBP)-1, -2, -3, and -4, nerve growth factor (NGF), and its receptor NGF-receptor (NGF-R), transforming growth factor-beta (TGF-beta), and basic fibroblast growth factor (bFGF), in normal thyroid tissue and various thyroid tumors. We applied the streptavidin-biotin technique to formalin-fixed, paraffin-embedded tissues. We studied 8-16 different cases of each of the following: normal human thyroid, multinodular hyperplasia, follicular adenoma, papillary carcinoma, follicular carcinoma, medullary carcinoma, and anaplastic carcinoma. EGF, TGF-alpha, and their receptor EGF-R were widely expressed in normal thyroid and in all the thyroid lesions examined. IGF-1 and IGFBP-1 were diffusely present in all different thyroid tissues as well. There was no difference in staining intensity or distribution that correlated with the pathological process. IGFBP-4 seemed to have a variable expression. IGFBP-2 and -3 were detected only in medullary carcinomas.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7787437     DOI: 10.1089/thy.1995.5.67

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  28 in total

1.  Do Statins Affect Thyroid Volume and Nodule Size in Patients with Hyperlipidemia in a Region with Mild-to-Moderate Iodine Deficiency? A Prospective Study.

Authors:  Canan Demir; Cuneyd Anil; Yusuf Bozkus; Umut Mousa; Altug Kut; Asli Nar; Neslihan B Tutuncu
Journal:  Med Princ Pract       Date:  2018-01-23       Impact factor: 1.927

2.  Laminin-5γ-2 (LAMC2) is highly expressed in anaplastic thyroid carcinoma and is associated with tumor progression, migration, and invasion by modulating signaling of EGFR.

Authors:  Manoj Garg; Deepika Kanojia; Ryoko Okamoto; Saket Jain; Vikas Madan; Wenwen Chien; Abhishek Sampath; Ling-Wen Ding; Meng Xuan; Jonathan W Said; Ngan B Doan; Li-Zhen Liu; Henry Yang; Sigal Gery; Glenn D Braunstein; H Phillip Koeffler
Journal:  J Clin Endocrinol Metab       Date:  2013-12-20       Impact factor: 5.958

3.  Expression of the estrogen receptor α, progesterone receptor and epidermal growth factor receptor in papillary thyroid carcinoma tissues.

Authors:  Dan Chen; Wenjing Qi; Pengxin Zhang; Hongwei Guan; Lifen Wang
Journal:  Oncol Lett       Date:  2015-05-19       Impact factor: 2.967

4.  Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers.

Authors:  Sofia Levva; Vassiliki Kotoula; Ioannis Kostopoulos; Kyriaki Manousou; Christos Papadimitriou; Kyriaki Papadopoulou; Sotiris Lakis; Kyriakos Koukoulias; Vasilios Karavasilis; George Pentheroudakis; Eufemia Balassi; Flora Zagouri; Ioannis G Kaklamanos; Dimitrios Pectasides; Evangelia Razis; Gerasimos Aravantinos; Pavlos Papakostas; Dimitrios Bafaloukos; Grigorios Rallis; Helen Gogas; George Fountzilas
Journal:  Cancer Genomics Proteomics       Date:  2017 May-Jun       Impact factor: 4.069

5.  Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options.

Authors:  Francesco Perri; Giuseppe Di Lorenzo; Giuseppina Della Vittoria Scarpati; Carlo Buonerba
Journal:  World J Clin Oncol       Date:  2011-03-10

6.  Predicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modelling.

Authors:  Ben-Fillippo Krippendorff; Diego A Oyarzún; Wilhelm Huisinga
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-03-08       Impact factor: 2.745

Review 7.  The IGF system in thyroid cancer: new concepts.

Authors:  V Vella; L Sciacca; G Pandini; R Mineo; S Squatrito; R Vigneri; A Belfiore
Journal:  Mol Pathol       Date:  2001-06

8.  Thyroid follicular oncogenesis in iodine-deficient and iodine-sufficient areas: search for alterations of the ras, met and bFGF oncogenes and of the Rb anti-oncogene.

Authors:  L Bartolone; F Vermiglio; M D Finocchiaro; M A Violi; D French; A Pontecorvi; F Trimarchi; S Benvenga
Journal:  J Endocrinol Invest       Date:  1998-11       Impact factor: 4.256

9.  TGFB, TGFB Receptors, Ki-67, and p27(Kip)l Expression in Papillary Thyroid Carcinomas.

Authors:  Ricardo V. Lloyd; Jorge A. Ferreiro; Long Jin; Tom J. Sebo
Journal:  Endocr Pathol       Date:  1997       Impact factor: 3.943

10.  Analysis of TGF-B and TGF-B-RII in Thyroid Neoplasms from the United States, Japan, and China.

Authors:  Yoshiaki Imamura; Long Jin; Joseph P. Grande; Chin-Yang Li; T-R. Zheng; Lori A. Erickson; Ricardo V. Lloyd
Journal:  Endocr Pathol       Date:  1998       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.